SCHEMBL4426600

SCHEMBL4426600

O=C(O)c1ccc(CNS(=O)(=O)C2CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.61
TSHR P16473 2/20 0.49
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 3/20 0.46
FABP4 P15090 1/20 0.43
POLB P06746 3/20 0.42
KDM4E B2RXH2 1/20 0.42
RECQL P46063 1/20 0.42
HPGD P15428 2/20 0.42
SSTR3 P32745 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HSD17B10 Q99714 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
MEP1B Q16820 1/20 0.42
GRIA2 P42262 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3811125 0.81 CA12 (0.59) KMT2AALDH1A1POLBKDM4EL3MBTL1
SCHEMBL6050992 0.78 CA2 (0.49) KMT2AMEN1POLBGRIA2TDP1
SCHEMBL1115782 0.78 CA2 (0.50) KMT2ATSHRALDH1A1MEN1RECQL
SCHEMBL15721401 0.78 KMT2A (0.53) KMT2AALDH1A1MEN1KDM4EHPGD
SCHEMBL2315910 0.77 GRIA2 (0.42) KMT2AMEN1GRIA2
SCHEMBL15684077 0.76 KMT2A (0.69) KMT2ATSHRALDH1A1POLBKDM4E
SCHEMBL2841195 0.76 KMT2A (1.00) KMT2ATSHRALDH1A1MEN1FABP4
Hydrochloric Acid SCHEMBL3526720 0.75 KMT2A (0.96) KMT2ATSHRALDH1A1MEN1FABP4
SCHEMBL4978574 0.75 SMN1; SMN2 (0.51) TSHRALDH1A1POLBL3MBTL1GRIA2
SCHEMBL8231364 0.75 HDAC4 (0.54) KMT2ATSHRALDH1A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024359-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DECEASE AND/OR SCHIZOPHRENIA AstraZeneca AB (SE) 2009-02-18 EP disclosed
WO-2007126362-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA ASTRAZENECA AB (SE) 2007-11-08 WO disclosed
WO-2007126362-A1 COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA ASTRAZENECA AB (SE) 2007-11-08 WO disclosed
US-20070259888-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-11-08 US disclosed
US-20070259888-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-11-08 US disclosed
US-20070259888-A1 Novel Compounds ASTRAZENECA AB (SE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259888-A1 Novel Compounds OPRL1, OPRM1, SIGMAR1 KMT2A 3736/4885TSHR 1580/4885ALDH1A1 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.